Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 529Neoplasms 494Carcinoma, Non-Small-Cell Lung 404Prostatic Neoplasms 309Colorectal Neoplasms 293Lung Neoplasms 272Neoplasm Metastasis 225Leukemia, Myeloid, Acute 214Ovarian Neoplasms 197Pancreatic Neoplasms 188Multiple Myeloma 181Squamous Cell Carcinoma of Head and Neck 141Recurrence 139Stomach Neoplasms 137Brain Neoplasms 131Melanoma 129Carcinoma, Hepatocellular 128Endometrial Neoplasms 118Triple Negative Breast Neoplasms 116Glioblastoma 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 108Hematologic Neoplasms 99Head and Neck Neoplasms 99Urinary Bladder Neoplasms 97Carcinoma, Renal Cell 97Lymphoma 95Glioma 90Sarcoma 89Esophageal Neoplasms 87Lymphoma, Large B-Cell, Diffuse 84

Interventions

darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × High-Risk Localized Prostate Cancer × 90 days × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡